Lotte to buy BMS biomedicine plant for $160 mln

김은정 / 2022-05-13 19:25:38
  • facebookfacebook
  • twittertwitter
  • kakaokakao
  • pinterestpinterest
  • navernaver
  • bandband
  • -
  • +
  • print
Lotte-bio biz
▲ U.S. drugfirm Bristol Myers Squibb's biologics factory in Syracuse is seen in this photo provided by Lotte Holdings Co. on May 13, 2022. (Yonhap)

Lotte-bio biz

Lotte to buy BMS biomedicine plant for $160 mln

SEOUL, May 13 (Yonhap) -- South Korea's Lotte Group decided Friday to buy U.S. drug firm Bristol Myers Squibb (BMS)'s pharmaceutical factory in Syracuse, New York, for $160 million.

Lotte's board of directors approved the deal, which also includes BMS's contract manufacturing agreements to produce medicine worth $220 million over the next three years.

Lotte said it also plans to make additional investment to establish a contract development and manufacturing organization (CDMO) and have production capacity for commercial biological products and cell and genetic treatment.

The retail-to-chemical conglomerate said the deal is part of its broader plan to invest 2.5 trillion won ($1.9 billion) in the bio business over the next decade to become a major player in the sector.


(C) Yonhap News Agency. All Rights Reserved